Who won EIC Accelerator Open 2022? 155 companies funded
- 145funded projects
- €337.3MEU contribution
- 155companies, 153 SMEs
- 23countries
Grant topic: EIC Accelerator Open
The European Commission funded 145 projects under the Horizon Europe topic HORIZON-EIC-2022-ACCELERATOROPEN-01, with €337.3M in total EU contribution. 155 private companies from 23 countries took part, and 153 of them are SMEs. Below is who they are, what they are building, and how much each received.
At a glance
- Funded projects: 145
- Total EU contribution: €337.3M
- Of which to companies: €329.9M (98%)
- Companies / of which SMEs: 155 / 153
- Average consortium size: 1.1 organisations
- Projects coordinated by a company: 142 of 145
- Top countries (company participations): Germany (24), France (24), the Netherlands (20), Spain (12)
Most company participations came from Germany, France and the Netherlands. Here is where every winning company is based:
Where the winning companies are based
Companies that received funding
These are the 12 companies that received the most EU funding under this topic, largest first. The chart compares the top amounts; blue bars are SMEs.
Where the money went
Advanced Brain Companion Diagnostics Spain SL
Sevilla, Spain · SME · project coordinator
Received €2.8M as a coordinator in LVOCheck: Diagnosis of large vessel occlusion (LVO) in acute stroke for improving access to treatment (2023-05 to 2025-04).
Vesselsens GmbH
Bonn, Germany · SME · project coordinator
Received €2.5M as a coordinator in StentGuard: Clinical validation of the First Implantable Sensor System for Wireless detection of stent occlusion/ restenosis (2022-10 to 2025-07).
Thericon GmbH
Mannheim, Germany · SME · project coordinator
Received €2.5M as a coordinator in rMSI: Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery (2022-10 to 2024-09).
Predisurge
Saint-Etienne, France · SME · project coordinator
Received €2.5M as a coordinator in Confident: Confident®, the digital simulation platform that revolutionizes cardiovascular interventions (2022-11 to 2024-10).
Brainever
Paris, France · SME · project coordinator
Received €2.5M as a coordinator in HOMEOBRAIN: Homeoproteins as novel therapies for neurodegenerative diseases (2022-11 to 2024-10).
Hy2care BV
Geleen, the Netherlands · SME · project coordinator
Received €2.5M as a coordinator in ACTIVE: Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective (2022-10 to 2024-09).
Neos New Born Solutions SL
Madrid, Spain · SME · project coordinator
Received €2.5M as a coordinator in NEOSONICS: The first medical device for non-invasive detection and monitoring of infant meningitis (2022-12 to 2025-08).
Perha Pharmaceuticals SAS
Roscoff, France · SME · project coordinator
Received €2.5M as a coordinator in DOWN-AUTONOMY: LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome. (2022-06 to 2026-06).
Cailabs
Rennes, France · SME · project coordinator
Received €2.5M as a coordinator in CROCUS: Coherent Rapid Optical Communication Under the Stratosphere (2022-06 to 2024-06).
Loci Orthopaedics Limited
Galway, Ireland · SME · project coordinator
Received €2.5M as a coordinator in InDx CMC Implant: The InDx CMC Implant. A new treatment for thumb base joint arthritis. (2022-11 to 2024-04).
Hemispherian AS
Oslo, Norway · SME · project coordinator
Received €2.5M as a coordinator in CureGLIO: Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology. (2023-01 to 2025-12).
Reliefed AB
Varberg, Sweden · SME · project coordinator
Received €2.5M as a coordinator in Reliefed: 3D tab cooled Battery pack solution based on an innovative 3D extrusion manufacturing process to better manage thermal regulation of EV batteries (2023-01 to 2026-09).
Also funded: Glucoset AS (NO), Ezmems Ltd (IL), Fineheart (FR), Atxa Therapeutics Ltd (IE), Centre de Recherche et de Developpement des Anatides du Courtalet (FR), Meletios Therapeutics (FR), Treble Technologies Ehf (IS), Amsimcel SRL (RO), Porous GmbH (DE), Axiles Bionics (BE), Time Is Brain SL (ES), E-Peas (BE), Herantis Pharma Oyj (FI), 3deus Dynamics SAS (FR), Antabio (FR), Eyelights (FR), Carmat (FR), Nexdot (FR), Elicit Plant (FR), Arctic Therapeutics Ehf (IS), CORTEC GmbH (DE), P3 Lab (BE), Sonio (FR), Blue Planet Ecosystems GmbH (AT), Ionctura BV (NL), Saia Agrobotics BV (NL), Neuronsw SE (CZ), Connecting Food (FR), Immunethep (PT), Aquab Nanobubble Innovations Limited (IE), Elicera Therapeutics AB (SE), Selio Medical Limited (IE), Adjucor GmbH (DE), Codasip GmbH (DE), Restore Medical Ltd (IL), Go-Pen ApS (DK), Endoron Medical Ltd (IL), OIVI AS (NO), Inphocal BV (NL), Protinhi BV (NL), and 103 more.
The funded projects
The 145 projects started between June 2022 and August 2023, and the last is due to finish in January 2027.
When the funded projects run
The ten largest of 145 projects by EU contribution:
LVOCheck: Diagnosis of large vessel occlusion (LVO) in acute stroke for improving access to treatment
€2.8M EU contribution · 1 partner · 2023-05 to 2025-04 · coordinated by Advanced Brain Companion Diagnostics Spain SL (ES)
LVOCheck is a portable diagnostic solution providing fast identification of large vessel occlusion (LVO) in acute stroke, just by analysing a blood drop from the patient's fingerpick. LVOCheck allows rapid triage of stroke patients already in the ambulance, so patients suffering a LVO can be directly driven to the closest thrombectomy centre to get the clot removed, without the need of a cranial CT scan at the…
StentGuard: Clinical validation of the First Implantable Sensor System for Wireless detection of stent occlusion/ restenosis
€2.5M EU contribution · 1 partner · 2022-10 to 2025-07 · coordinated by Vesselsens GmbH (DE)
Globally, over 237 million people suffer from peripheral artery disease (PAD), an abnormal narrowing of the arteries. The implantation of stents (spiral wire protheses) is the first-line therapy for PAD with ~ 3.5M stents implanted worldwide every year.
rMSI: Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery
€2.5M EU contribution · 1 partner · 2022-10 to 2024-09 · coordinated by Thericon GmbH (DE)
Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information, along the limitations of current imaging technologies, which make it difficult for surgeons to differentiate between different types of tissue.
Confident: Confident®, the digital simulation platform that revolutionizes cardiovascular interventions
€2.5M EU contribution · 1 partner · 2022-11 to 2024-10 · coordinated by Predisurge (FR)
Confident is a disruptive cloud-based platform for digital planning of cardiovascular interventions. Today, many patients do not have access to treatment as their case is considered at too high risk for surgery. Created in 2017, PrediSurge has developed a unique AI-based solution that enables physicians to select the best therapeutic strategy for a specific patient.Confident®builds 3D virtual models of patients’…
HOMEOBRAIN: Homeoproteins as novel therapies for neurodegenerative diseases
€2.5M EU contribution · 1 partner · 2022-11 to 2024-10 · coordinated by Brainever (FR)
With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases. At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs).
ACTIVE: Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective
€2.5M EU contribution · 1 partner · 2022-10 to 2024-09 · coordinated by Hy2care BV (NL)
Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthroscopy. The hydrogel fill the defect, prevents ingrowth of scar tissue and allows the body to heal itself by creating true Hyaline cartilage, ensuring an optimal regenerated tissue.
NEOSONICS: The first medical device for non-invasive detection and monitoring of infant meningitis
€2.5M EU contribution · 1 partner · 2022-12 to 2025-08 · coordinated by Neos New Born Solutions SL (ES)
Meningitis is a life-threatening disease that can kill in a matter of hours or cause life-long disabilities if not detected promptly. Infants (<12 months) are the most vulnerable population with a compromised immunologic system.
DOWN-AUTONOMY: LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.
€2.5M EU contribution · 1 partner · 2022-06 to 2026-06 · coordinated by Perha Pharmaceuticals SAS (FR)
All people with Down Syndrome (DS) suffer from a certain level of impaired learning and memory (cognitive disorders) from childhood onwards, greatly impacting their autonomy and societal integration. This is becoming an increasingly urgent issue as people with DS are more often outliving their care takers, yet an adequate treatment has not yet been developed.Studies have revealed that the cognitive decline in people…
CROCUS: Coherent Rapid Optical Communication Under the Stratosphere
€2.5M EU contribution · 1 partner · 2022-06 to 2024-06 · coordinated by Cailabs (FR)
Communication is the heart of our society. However, 1/3 of the world population still does not have access to the internet, while the appetite for connectivity is growing worldwide. As RF networks are reaching their limits in bandwidth, spectrum and security, new architectures are required to reach all populations and support increase in traffic.
InDx CMC Implant: The InDx CMC Implant. A new treatment for thumb base joint arthritis.
€2.5M EU contribution · 1 partner · 2022-11 to 2024-04 · coordinated by Loci Orthopaedics Limited (IE)
The InDx CMC Implant is for the treatment of thumb base joint arthritis. It is the first evidence-based, surgeon-led innovation, implant solution for this major clinical problem. The potential market is estimated at over €700M per year.The implant meets a major unmet clinical need for an ageing EU population.
What the winning consortia had in common
- Consortia averaged 1.1 organisations, and companies held 155 of 158 seats (98%).
- 99% of company seats went to SMEs, so smaller firms clearly had room in these consortia.
- 142 of 145 projects were coordinated by a company; the rest were led by universities, research organisations or public bodies.
Here is how all 158 organisations in these consortia break down by type:
Who sits at the table
See the original call on Grantalist.
Source: CORDIS Horizon Europe open data, © European Union, reused under CC BY 4.0. Figures are the EU contribution recorded at grant signature; data as of 2026-08-28.